~~Table~~As offiled ~~Contents~~with the Securities and Exchange Commission on June 23, 2006

AsUNITED ~~filed~~STATES SECURITIES ~~with~~AND ~~the~~EXCHANGE ~~Securities and Exchange Commission on May 2, 2006~~COMMISSION

~~UNITED~~Washington, ~~STATES~~D.C. ~~SECURITIES AND EXCHANGE COMMISSION~~20549

~~Washington,~~FORM ~~D.C. 20549~~8-K

~~FORM~~CURRENT ~~8-K~~REPORT

~~CURRENT~~PURSUANT ~~REPORT~~TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

~~PURSUANT~~Date of TOReport ~~SECTION 13 OR 15~~(d)Date ~~OF THE~~of ~~SECURITIES~~earliest ~~EXCHANGE~~event ~~ACT~~reported): OFJune 23, ~~1934~~ 2006

~~Date~~Diagnostic ofProducts ~~Report (Date of earliest event reported): April 26, 2006~~Corporation

~~Diagnostic~~(Exact ~~Products~~name ~~Corporation~~ of registrant as specified in its charter)

California (~~Exact~~State ~~name~~or other jurisdiction of ~~registrant~~incorporation asor ~~specified~~organization) in1-9957 ~~its~~(Commission ~~charter~~File Number) 95-2802182 (I.R.S. Employer Identification No.)

California	1-9957	95-2802182
(State or other jurisdiction of	(Commission File Number)	(I.R.S. Employer
incorporation or organization)		Identification No.)

5210 Pacific Concourse Drive, Los Angeles, California 90045
(Address of principal executive offices) (Zip code)

~~5210~~Registrant’s ~~Pacific~~telephone ~~Concourse Drive~~number, ~~Los~~including ~~Angeles,~~area ~~California~~code: ~~90045~~ (~~Address of principal executive offices~~310) ~~(Zip code)~~ 645-8200

~~Registrant’s~~Not ~~telephone~~Applicable (Former ~~number~~name or former address, ~~including~~if ~~area~~changed ~~code:~~since ~~(310~~last report) ~~645-8200~~

~~Not~~Check ~~Applicable~~the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy ~~(Former~~the ~~name~~filing orobligation ~~former~~of ~~address,~~the ifregistrant ~~changed~~under ~~since~~any ~~last~~of ~~report~~the following provisions (see General Instruction A.2. below):

~~Check~~¨ ~~the~~Written ~~appropriate~~communications ~~box~~pursuant ~~below if the Form 8-K filing is intended~~ to ~~simultaneously~~Rule 425 ~~satisfy the filing obligation of the registrant~~ under ~~any of~~ the ~~following~~Securities ~~provisions~~Act (~~see~~17 ~~General Instruction~~CFR A230.~~2. below~~425):

oý ~~Written~~Soliciting ~~communications~~material pursuant to Rule ~~425~~14a-12 under the ~~Securities~~Exchange Act (17 CFR ~~230~~240.~~425~~14a-12)

o¨ ~~Soliciting~~Pre-commencement ~~material~~communications pursuant to Rule ~~14a~~14d-12 2(b) under the Exchange Act (17 CFR 240.~~14a~~14d-122(b))

o¨ Pre-commencement communications pursuant to Rule ~~14d~~13e-24(bc) under the Exchange Act (17 CFR 240.~~14d~~13e-24(bc))

~~o Pre-commencement communications pursuant to Rule~~Item ~~13e-4(c) under~~8.01. ~~the~~Other ~~Exchange Act (17 CFR 240~~Events.~~13e-4(c))~~

~~TABLE~~ On OFJune 23, ~~CONTENTS~~2006, Diagnostic Products Corporation (the “Company”) issued a press release. The press release announced that on June 22, 2006, the Medical Solutions Group of Siemens AG received notification of clearance from the German Federal Cartel Office to proceed with the proposed acquisition of the Company pursuant to the previously announced merger agreement between Siemens Medical Solutions USA, Inc., and the Company.

~~Item~~ A ~~1.01.~~copy ~~Entry~~of ~~into~~the aCompany’s ~~Material~~press ~~Definitive~~release ~~Agreement~~is ~~Item~~being 9furnished as Exhibit 99.~~01.~~1 ~~Financial~~to ~~Statements~~this Form 8-K and is ~~Exhibits~~incorporated ~~SIGNATURE~~herein ~~Exhibit~~by 10reference in its entirety.1

~~Table~~Item 9.01. ofFinancial ~~Contents~~Statements and Exhibits.

~~Item 1.01.~~(c) ~~Entry into a Material Definitive Agreement~~Exhibits.

Change in Control Severance Agreements


Exhibit
Number		Description of Exhibit
99.1		Press release issued by Diagnostic Products Corporation and Siemens Medical Solutions on June 23, 2006.

~~On April 26, 2006, the Board of Directors of Diagnostic Products Corporation (the “Company”)~~SIGNATURE approved the Company’s entry into Change in Control Severance Agreements (the “Agreements”) with each of the following individuals: Sidney Aroesty (President, Chief Operating Officer, and a Director of the Company); James Brill (Vice President, Finance and Chief Financial Officer of the Company); Douglas Olson (Chief Scientific Officer of the Company and President, Instrument Systems Division); and Fritz Backus (General Counsel of the Company) (collectively, the “Officers”). The initial term of each Agreement is twelve months, with automatic one-year extensions unless the Compensation Committee of the Company’s Board of Directors delivers written notice of non-renewal to the Officer at least six months prior to the end of the initial or extended term.

~~Each~~Pursuant ~~Agreement provides that the Officer will be entitled~~ to ~~certain severance benefits if, within twenty-four months following a Change in Control (as defined therein),~~ the ~~Officer~~requirements ~~experiences a qualifying termination~~ of ~~employment with~~ the ~~Company~~Securities (aExchange ~~“Qualifying~~Act Termination”). The severance benefits include lump sum payments related to the Officer’s salary, bonus, and qualified retirement plan account; a lump sum payment for outplacement services for the Officer for the eighteen-month period following the Qualifying Termination; and continuation of ~~the Officer’s medical and dental coverage~~1934, ~~and car allowance and other Company car perquisites, for~~ the ~~eighteen-month~~registrant ~~period following~~has ~~the~~duly ~~Qualifying Termination. The Agreements also provide for a “gross-up” payment to the~~caused ~~Officer~~this inreport the event that the payment of the severance benefits upon or following a Change in Control, when aggregated with any other payments the Officer may receive in connection with the Change in Control, result in the Officer being subject to ~~the~~be ~~excise~~signed ~~tax~~on ~~imposed~~its behalf by ~~Section 4999 of~~ the ~~Internal~~undersigned ~~Revenue~~hereunto ~~Code~~duly ~~(the “Excise Tax”)~~authorized. ~~The gross-up payment is designed to place the~~ Officer in the same after-tax position with respect to the payment of severance and other benefits in connection with a Change in Control that the Officer would have been in had the Excise Tax not been imposed.

A copy of the form of Agreement is attached hereto as Exhibit 10.1 and is herein incorporated by reference. The foregoing description of the Agreement is qualified in its entirety by reference to the full text of the Agreement.


	DIAGNOSTIC PRODUCTS CORPORATION
Dated: June 23, 2006	By:	/s/ James L. Brill
		Name:	James L. Brill
		Title:	Vice President, Finance and Chief Financial Officer

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit
Number		Description of Exhibit
10.1		Diagnostic Products Corporation Form of Change in Control Severance Agreement.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	DIAGNOSTIC PRODUCTS CORPORATION
Dated: May 2, 2006	By:	/s/ James L. Brill
	Name:	James L. Brill
	Title:	Vice President, Finance and Chief Financial Officer

Table of Contents

Filing Compare · DIAGNOSTIC PRODUCTS CORP